Xinchen Wang1, Qing Liu1, Óskar Ö Halfdanarson2, Helga Zoega2,3, Omid Sadr-Azodi4, Lars Engstrand1, Katja Fall5,6, Nele Brusselaers7,8,9. 1. Centre for Translational Microbiome Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden. 2. Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland. 3. Medicines Policy Research Unit, Centre for Big Data Research in Health, UNSW, Sydney, NSW, Australia. 4. Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. 6. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden. 7. Centre for Translational Microbiome Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden. nele.brusselaers@ki.se. 8. Global Health Institute, Antwerp University, Antwerpen, Belgium. nele.brusselaers@ki.se. 9. Department of Head and Skin, Ghent University, Ghent, Belgium. nele.brusselaers@ki.se.
Abstract
BACKGROUND: Proton pump inhibitors (PPIs) are associated with microbiome changes of the gut, which in turn may affect the progression of colorectal cancer (CRC). This study aims to assess the associations between PPI use and all-cause and CRC-specific mortality. METHODS: We selected all patients registered in the Swedish Prescribed Drug Registry who were diagnosed with CRC between 2006 and 2012 (N = 32,411, 54.9% PPI users) and subsequently followed them through register linkage to the Swedish Causes of Death Registry until December 2013. PPI users were patients with ≥1 post-diagnosis PPI dispensation. Time-dependent Cox-regression models were performed with PPI use as time-varying exposure. RESULTS: Overall 4746 (14.0%) patients died, with an aHR of 1.38 (95% CI 1.32-1.44) for all-cause mortality comparing PPI users with PPI nonusers. Higher-magnitude associations were observed among male, cancer stage 0-I, rectal cancer and patients receiving CRC surgery. The PPI-all-cause mortality association was also more pronounced comparing new users to non-users (aHR = 1.47, 95%CI 1.40-1.55) than comparing continuous users to non-users (aHR = 1.32, 95%CI 1.24-1.39). The risk estimates for CRC-specific mortality comparing PPI users to PPI nonusers were similar to those for all-cause mortality. CONCLUSION: PPI use after the CRC diagnosis was associated with increased all-cause and CRC-specific mortality.
BACKGROUND: Proton pump inhibitors (PPIs) are associated with microbiome changes of the gut, which in turn may affect the progression of colorectal cancer (CRC). This study aims to assess the associations between PPI use and all-cause and CRC-specific mortality. METHODS: We selected all patients registered in the Swedish Prescribed Drug Registry who were diagnosed with CRC between 2006 and 2012 (N = 32,411, 54.9% PPI users) and subsequently followed them through register linkage to the Swedish Causes of Death Registry until December 2013. PPI users were patients with ≥1 post-diagnosis PPI dispensation. Time-dependent Cox-regression models were performed with PPI use as time-varying exposure. RESULTS: Overall 4746 (14.0%) patients died, with an aHR of 1.38 (95% CI 1.32-1.44) for all-cause mortality comparing PPI users with PPI nonusers. Higher-magnitude associations were observed among male, cancer stage 0-I, rectal cancer and patients receiving CRC surgery. The PPI-all-cause mortality association was also more pronounced comparing new users to non-users (aHR = 1.47, 95%CI 1.40-1.55) than comparing continuous users to non-users (aHR = 1.32, 95%CI 1.24-1.39). The risk estimates for CRC-specific mortality comparing PPI users to PPI nonusers were similar to those for all-cause mortality. CONCLUSION: PPI use after the CRC diagnosis was associated with increased all-cause and CRC-specific mortality.
Authors: Douglas J Robertson; Heidi Larsson; Søren Friis; Lars Pedersen; John A Baron; Henrik T Sørensen Journal: Gastroenterology Date: 2007-06-20 Impact factor: 22.682
Authors: Siri A Tvingsholm; Christian Dehlendorff; Kell Østerlind; Søren Friis; Marja Jäättelä Journal: Int J Cancer Date: 2018-05-02 Impact factor: 7.396
Authors: Peter D Siersema; Stanley Yu; Peyman Sahbaie; Ewout W Steyerberg; Peter W Simpson; Ernst J Kuipers; George Triadafilopoulos Journal: Gastrointest Endosc Date: 2006-04 Impact factor: 9.427
Authors: Eva M van Soest; Leo G M van Rossum; Jeanne P Dieleman; Martijn G H van Oijen; Peter D Siersema; Miriam C J M Sturkenboom; Ernst J Kuipers Journal: Am J Gastroenterol Date: 2007-12-05 Impact factor: 10.864
Authors: Jessica Chubak; Denise M Boudreau; Stephen J Rulyak; Margaret T Mandelson Journal: Pharmacoepidemiol Drug Saf Date: 2009-07 Impact factor: 2.890
Authors: Floris Imhann; Marc Jan Bonder; Arnau Vich Vila; Jingyuan Fu; Zlatan Mujagic; Lisa Vork; Ettje F Tigchelaar; Soesma A Jankipersadsing; Maria Carmen Cenit; Hermie J M Harmsen; Gerard Dijkstra; Lude Franke; Ramnik J Xavier; Daisy Jonkers; Cisca Wijmenga; Rinse K Weersma; Alexandra Zhernakova Journal: Gut Date: 2015-12-09 Impact factor: 23.059
Authors: Chun-Han Lo; Peiyun Ni; Yan Yan; Wenjie Ma; Amit D Joshi; Long H Nguyen; Raaj S Mehta; Paul Lochhead; Mingyang Song; Gary C Curhan; Yin Cao; Andrew T Chan Journal: Gastroenterology Date: 2022-07-01 Impact factor: 33.883
Authors: M Del Re; C Omarini; L Diodati; M Palleschi; I Meattini; S Crucitta; G Lorenzini; C Isca; A Fontana; L Livi; F Piacentini; S Fogli; U De Giorgi; R Danesi Journal: ESMO Open Date: 2022-02-04